Advancements in targeting CD30 for lymphoma therapy: a historical perspective and future directions.

IF 2.3 4区医学 Q2 HEMATOLOGY

Expert Review of Hematology Pub Date : 2025-04-01 Epub Date: 2025-05-11 DOI:10.1080/17474086.2025.2492936

Hongju Zhang, Yuting Yan, Shuhua Yi, Qi Sun

{"title":"Advancements in targeting CD30 for lymphoma therapy: a historical perspective and future directions.","authors":"Hongju Zhang, Yuting Yan, Shuhua Yi, Qi Sun","doi":"10.1080/17474086.2025.2492936","DOIUrl":null,"url":null,"abstract":"Introduction: CD30 is a transmembrane protein of the tumor necrosis factor receptor superfamily. It is expressed on a small subset of activated T and B lymphocytes, and various lymphoid neoplasms, including classical Hodgkin lymphoma and many non-Hodgkin lymphomas in both pediatric and adult populations.Areas covered: This review delves into the significance of CD30 as a therapeutic target and a prognostic indicator for various lymphomas. It provides a comprehensive overview of anti-CD30 therapeutic interventions developed to date, offering insights into the future direction of lymphoma treatment research. Literature search was conducted from January 1987 to December 2024 using PubMed, Scopus, and Web of Science databases to identify relevant studies.Expert opinion: CD30 has emerged as a critical marker of diagnosis, prognosis, and therapeutic strategies of lymphomas. The introduction of brentuximab vedotin (BV) (Adcetris), an antibody-drug conjugate targeting CD30, has significantly advanced the treatment landscape for multiple lymphoma types, demonstrating enhanced efficacy and manageable safety profiles in CD30+ lymphomas patients. However, drug resistance is observed in few patients. Concurrently, innovative therapeutic strategies targeting CD30, such as chimeric antigen receptor T-cells therapies and bispecific antibodies, are in development. This underscores a strong and ongoing research effort aimed at improving the management of patients with CD30+ lymphomas.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"373-386"},"PeriodicalIF":2.3000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2025.2492936","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: CD30 is a transmembrane protein of the tumor necrosis factor receptor superfamily. It is expressed on a small subset of activated T and B lymphocytes, and various lymphoid neoplasms, including classical Hodgkin lymphoma and many non-Hodgkin lymphomas in both pediatric and adult populations.

Areas covered: This review delves into the significance of CD30 as a therapeutic target and a prognostic indicator for various lymphomas. It provides a comprehensive overview of anti-CD30 therapeutic interventions developed to date, offering insights into the future direction of lymphoma treatment research. Literature search was conducted from January 1987 to December 2024 using PubMed, Scopus, and Web of Science databases to identify relevant studies.

Expert opinion: CD30 has emerged as a critical marker of diagnosis, prognosis, and therapeutic strategies of lymphomas. The introduction of brentuximab vedotin (BV) (Adcetris), an antibody-drug conjugate targeting CD30, has significantly advanced the treatment landscape for multiple lymphoma types, demonstrating enhanced efficacy and manageable safety profiles in CD30+ lymphomas patients. However, drug resistance is observed in few patients. Concurrently, innovative therapeutic strategies targeting CD30, such as chimeric antigen receptor T-cells therapies and bispecific antibodies, are in development. This underscores a strong and ongoing research effort aimed at improving the management of patients with CD30+ lymphomas.

查看原文本刊更多论文

靶向CD30治疗淋巴瘤的进展：历史展望和未来方向。

CD30是肿瘤坏死因子受体超家族中的一种跨膜蛋白。它在一小部分活化的T淋巴细胞和B淋巴细胞以及各种淋巴样肿瘤中表达，包括儿童和成人人群中的经典霍奇金淋巴瘤和许多非霍奇金淋巴瘤。涵盖领域：本综述深入探讨了CD30作为各种淋巴瘤的治疗靶点和预后指标的意义。它提供了迄今为止抗cd30治疗干预措施的全面概述，为淋巴瘤治疗研究的未来方向提供了见解。文献检索从1987年1月至2024年12月，使用PubMed、Scopus和Web of Science数据库进行检索，以确定相关研究。专家意见：CD30已成为淋巴瘤诊断、预后和治疗策略的关键标志物。brentuximab vedotin (BV) （Adcetris）是一种靶向CD30的抗体-药物偶联物，它的引入显著推进了多种淋巴瘤类型的治疗前景，在CD30+淋巴瘤患者中显示出更高的疗效和可管理的安全性。然而，在少数患者中观察到耐药性。同时，针对CD30的创新治疗策略，如嵌合抗原受体t细胞疗法和双特异性抗体，正在开发中。这强调了一项旨在改善CD30+淋巴瘤患者管理的强大且正在进行的研究工作。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Hematology HEMATOLOGY-

CiteScore

4.70

自引率

3.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.